インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］ shortage — JP supply status & alternatives

インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］

—

In supply · Australia

インフリキシマブＢＳ点滴静注用１００ｍｇ「あゆみ」

In supply · 🇦🇺 Australia · short in🇯🇵 JP

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］

Therapeutic category	Auto-created by Ministry of Health, Labour and Welfare — Drug Supply Status scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Verified timeline regulator events

🇯🇵 1 July 2026

critical reported

🇯🇵 20 June 2026

critical reported

🇯🇵 18 June 2026

critical reported

🇯🇵 10 June 2026

critical reported

🇯🇵 8 June 2026

critical reported

🇯🇵 4 June 2026

critical reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.